A Phase 1 Study of TERN-701 in People With Chronic Myeloid Leukemia

Full Title

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia

Purpose

Researchers want to find the best dose of TERN-701 to use in people with chronic myeloid leukemia (CML). The people in this study have CML that came back after treatment or could not be treated with standard therapies.

TERN-701 blocks a protein called BCR::ABL1, which causes cancer cells to multiply and grow. By blocking this protein, this drug may cause your cancer cells to die. TERN-701 blocks BCR::ABL1 differently than similar drugs for CML. This may make it more useful if other CML drugs have not worked for you. TERN-701 is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Michael Mauro’s office at 646-608-3744.